CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study

Stock Information for CASI Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Announces Changes in Board Governance
CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results
CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ
CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference
CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual Meeting
CASI Pharmaceuticals Appoints James Huang to Board of Directors
CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.